Drug intermediates are the drugs used as raw materials for the production of bulk drugs, or they can refer to a material produced during synthesis of an API that must undergo further molecular change or processing before it becomes an API. Drug intermediates are hygienically formulated using high grade raw materials and they are used in the pharmaceutical and cosmetic industry. Pharmaceutical companies use drugs intermediates for research and development purposes. Pharmaceutical intermediates, veterinary drug intermediates, and bulk drug intermediates are various types of drug intermediates. The global drug intermediate market is expected to grow at a high rate owing to rising research and development activity globally.

Read Report Overview - https://www.transparencymarketresearch.com/drug-intermediate-market.html

The market of drug intermediates is segmented on the basis of type of intermediate, end user, and by region. On the basis of type of intermediate, the market is segmented into two main types, API intermediate, and advanced intermediate. API or active pharmaceutical ingredient intermediates are the raw materials or raw drugs responsible for therapeutic action. They are the active ingredients which are later converted into various forms such as tablets, capsules, suspensions etc. API acts as a drug itself. Advanced intermediates are advanced forms of drug intermediates. Advanced intermediate drugs are used to perform drug interaction activity which formed in new chemical products. Capecitabine intermediates, imatinib intermediates, lenalidomide intermediates, pemetrexed intermediates, nilotinib intermediates, temozolamide intermediates, gemcitabine intermediates, afatinib intermediates, pazopanib intermediates, and ibrutinib intermediates are few examples of drug intermediates.

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=31493

On the basis of end user, the global drug intermediate market is segmented into pharmaceutical industry, biotechnology industry, and chemical industry. Drug intermediates are available in various forms such as moderate quality drug intermediates, high quality intermediates, and premium quality intermediates. The high and premium quality drug intermediates are used mainly for research purposes. There has been an ever increasing demand for drug intermediates in the global market due to the fast growing biotechnology and life sciences sectors, along with rising adoption and increasing application of drug intermediates in research fields. Pharmaceutical companies and biotechnology companies, along with research companies around the world have shown growing focus toward R&D in drug discovery and development, New methods and technologies in the equipment for synthesizing drug intermediate with manufacturers providing numerous customizations in the synthesized drugs, has widened the scope of applications and led to increasing demand for drug intermediate in the global market.

Request for Analysis of COVID-19 Impact on Drug Intermediate Market- https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=31493

By geography, the market for drug intermediates is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Asia Pacific leads the drug intermediate market owing to rising pharmaceutical and life sciences industry in the region especially in emerging markets in countries such as India and China. Europe is the second leading market for drug intermediates due to development and expansion of more efficient and advanced technologies. The Asia Pacific drug intermediate market is also anticipated to expand at an increasing rate owing to increasing healthcare spending, adoption of western lifestyle, and growth in research and development. Asia Pacific is the fastest growing region for the drug intermediate market as several players have invested in the development and manufacturing of drug intermediates. These factors are expected to drive the market growth of drug intermediates during the forecast period.

Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=31493

Key players in the global Drug Intermediate market are Ami Lifesciences, Accrete Pharmaceuticals Pvt. Ltd, A. B. Enterprises, Ramdev Chemicals Pvt. Ltd., Clearsynth, Aarti Drugs Ltd., Synpure Labs, and Karvy Therapeutics Pvt. Ltd among others. The rising competition in the pharmaceutical and biotechnology industry for outsourcing of drug intermediates and manufacturing of drug intermediates is expected to boost the growth of the global drug intermediate market during the forecast period.

Pre Book Drug Intermediate Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=31493&ltype=S

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

Browse More Trending Reports by Transparency Market Research:

Lumbar Stenosis Treatment Market: https://www.transparencymarketresearch.com/lumbar-stenosis-treatment-market.html

Intracranial Stenosis Treatment Market: https://www.transparencymarketresearch.com/intracranial-stenosis-treatment-market.html

Plastic Bandages Market: https://www.transparencymarketresearch.com/plastic-bandages-market.html

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

Contact

Mr. Rohit BhiseyTransparency Market Research

State Tower,

90 State Street,

Suite 700,

Albany NY - 12207

United States

USA - Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com/

See the original post here:
Drug Intermediate Market: Fast growing biotechnology and life sciences sectors is expected to drive the growth - BioSpace

Key Takeaways

In a new rule proposed September 1, the U.S. Environmental Protection Agency (EPA) announced its intent to streamline the regulatory requirements for certain plant-incorporated protectants (PIPs)regulated pesticidal substances produced by plants, as well as the genetic material necessary for the plant to produce those substances. Currently, only PIPs developed through conventional breeding are exempt from EPAs pesticide registration requirements. All other PIPs, including those developed using biotechnology, must be registered by EPA under the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) and must obtain a tolerance or exemption from tolerance for pesticide food residues under the Federal Food, Drug, and Cosmetic Act (FFDCA) prior to their distribution or sale.

EPAs proposed rule would expand this longstanding exemption to now include PIPs developed using biotechnology, as long as the new plant-produced pesticidal substance can already be found in plants that are sexually compatible with the recipient plant and EPAs proposed exemption criteria are otherwise met. Developers would be required to submit a self-determination letter or otherwise seek affirmative confirmation from EPA to utilize the exemption.

According to EPA, the proposal is intended to make the regulatory process more efficient and increase the availability of these innovative technologies, while continuing to ensure adequate safety. The proposed rule implements Executive Order 13874, 84 Fed. Reg. 27899 (June 11, 2019), Modernizing the Regulatory Framework for Agricultural Biotechnology Products, which directed EPA and other federal agencies to exempt low-risk products of agricultural biotechnology from undue regulation as permitted by law and grounded in scientific evidence. To learn more about this executive order, see our news alert here.

As of September 2, 2020, the proposed rule is still in pre-publication. EPA will accept comments from stakeholders and the public for 60 days following publication of the proposed rule in the Federal Register.

FIFRA prohibits the distribution or sale of any pesticide in the United States that is not first approved by and registered with EPA. A pesticide is defined broadly to include any substance or mixture of substances intended for preventing, destroying, repelling, or mitigating any pest. 7 U.S.C. 136(u). PIPs refer to pesticidal substances produced by a plant itself, along with the genetic material that allows the plant to do so. As pesticides under FIFRA, PIPs require registration before they may be distributed or sold. Over the last several decades, for example, EPA has registered dozens of insecticidal Bacillus thuringiensis (Bt) proteins introduced into corn, cotton, soybean, and other plants. Once these PIPs have been incorporated, the plants themselves are able to manufacture the pesticidal protein to control insects that feed on them. Although EPA regulates PIPs and their genetic material, it does not regulate the individual plants producing or containing the PIP.

As with conventional chemical pesticides, an applicant for a PIP registration must submit sufficient data to EPA to demonstrate that the pesticide at issue will present no unreasonable adverse effects to humans or the environment when used as intended. Moreover, under the FFDCA, EPA must also establish a tolerance (or exemption from a tolerance) before allowing any use of a pesticide that may result in residues in or on foods. Generating the extensive data necessary to support EPA registration and establishment of a tolerance can substantially increase the level of time and resources required to bring a new pesticide product to market.

In 2001, EPA promulgated regulations exempting certain PIPs from FIFRAs registration requirement if (1) the genetic material that encodes the pesticidal substance is from a plant that is sexually compatible with the recipient plant, and (2) that genetic material is not derived from a source that is not sexually compatible with the recipient plant. EPA further defined the term sexually compatible to include only conventional breeding, which has historically excluded any genetically engineered PIPs from the exemptions scope.

EPAs proposed rule would expand the existing exemption to include not only PIPs developed through conventional breeding but also certain PIPs developed using biotechnology. To accomplish this, EPA is proposing to add a new exemption to the Agencys regulations found at 40 CFR part 174, as well as to expand the existing definition of sexually compatible. To qualify for the new proposed exemption, a PIP developed using biotechnology will qualify for the new exemption if it:

PIP developers would be required to submit either a letter of self-determination or a request for EPA confirmation that a PIP based on a sexually compatible plant but created through biotechnology meets the criteria for exemption. Among other considerations, developers will need to weigh the potential benefits of relying on a self-determination letter, including the potential ability to bring a product to market more quickly, against the risk of a subsequent Agency determination that their PIP does not meet the new exemptions criteria.

Products exempt from registration under the proposed rule would also remain exempt from regulation under the recently revised USDA regulations at 7 CFR part 340, restricting the movement of certain genetically engineered organisms.

[View source.]

Read more from the original source:
EPA Proposes to Allow Certain Uses of Biotechnology in Development of Plant-Incorporated Protectants - JD Supra

Despite their ability to create matter out of thin air, algae and cyanobacteria have long been neglected by the biotech industry. Recently, however, they have started to gain traction in new market niches.

In the center of Paris, just across from Marie Curies old laboratory, Pierre Crozet, Associate Professor at Sorbonne University, studies photosynthesis. His research focuses on making microalgae easier to engineer and thus more appealing to the industry. [Microalgae] are photosynthetic, and quite efficient at it, but require much less space or nutrients than land plants, he told me.

The idea that new technologies should serve sustainability has started taking root in society. Using photosynthetic microbes for biotech applications appears to be a no-brainer. Algae grow biomass literally out of thin air, only needing water, carbon dioxide, and inorganic nutrients. Many grow on seawater and in lands not suitable for agriculture.

Today, we are managing quite well in transforming algae. I would thus not consider it particularly difficult, says Crozet, pointing out that, nowadays, obtaining a new strain of algae using genetic engineering takes just weeks. So, technically, they should be able to effectively replace bacteria and yeast, which generally require more complex growth facilities as well as the input of a sugar source in order to be able to generate any product.

However, algae have historically not been considered a good alternative to yeast and bacteria because of their slower growth rate. In addition, the crash of many algae biofuel companies about a decade ago dealt a blow to the field that it still has trouble recovering from.

The early 2010s saw several startups forming to produce biofuels, mainly in the US. Many claimed to be close to offering algal biofuel at competitive market prices. Sapphire Energy, Solazyme, and Algenol, among others, received significant public and private investments and built up high expectations. But due to technological challenges and the drop in oil prices between 2015 and 2016, no product became commercially viable and these businesses either went bankrupt or had to radically change their focus.

The [challenge] of algae and cyanobacteria comes down to their slow growth and the cost of production, says Hugh Goold, Research Scientist at the NSW Department of Primary Industries, Australia. According to Goold, the resources required to keep photosynthesis going is very high, meaning they dont replicate as quickly as the bacteria and yeast commonly used in biotech applications.

Bacteria and yeast have been optimized for many years in biotech applications such as producing commodity chemicals as well as high-value compounds such as pharmaceuticals, meaning that photosynthetic organisms can no longer compete with these applications. Investors have to know that you are going to produce a product cheaper than other people can. It isnt worthwhile to produce something in algae instead of E. coli just because, said Goold.

Despite this challenge, algae and cyanobacteria have started to get interest from new market niches where they could offer key advantages over traditional bioproduction methods.

Microalgae capture sunlight using pigments of vibrant colors, such as chlorophylls, carotenoids, and phycocyanin. In particular, the algae spirulina and chlorella found their way to the market a long time ago as food supplements and food colorants. Algae are also an excellent source of protein, which opens up a lot of opportunities in the production of meat analogs and vegan food in general.

Unilever, a massive producer of food and other consumer goods, has seen the nutritional potential of microalgae, partnering with UK-based company Algenuity in July. Algae are a source of high-quality plant-based protein, said Manfred Aben, Vice President of Science & Technology at Unilever. These products will appeal to a variety of consumers; for vegans and vegetarians but also for flexitarians and meat-eaters looking to reduce their consumption of animal products.

Within the food and beverage sector, the opportunities for microalgae-based ingredients are strong and tangible, explained Andrew Spicer, CEO of Algenuity. We do anticipate applications for microalgae-based ingredients in markets other than food and beverages where similar drivers around sustainability, plant-based, and natural sources of ingredients are equally strong.

Last year, the Dutch food and biochemical company Corbion announced a similar partnership with Nestl, signaling that big players in the food industry are starting to increasingly recognize the potential value of algae products. Other companies gaining traction in the field are Algama in France seeking to provide meat alternatives, and AlgaEnergy in Spain producing food and feed as well as cosmetics and fertilizers from algae.

In 2011, Renana Krebs graduated from the Shenkar College of Engineering, Design, and Art in Tel Aviv with a degree in fashion. While working for fashion brands, she realized the huge impact the industry has on the environment. Clothes and textiles manufacturing accounts for 10% of global carbon emissions and 20% of wastewater. Looking for alternative solutions, Krebs teamed up with her father and founded Algalife, a German-Israeli company offering algae-based fibers and textiles.

Algalife stands for a better planet and a better fashion industry. We provide and enable the opportunity for everyone to make better choices, for a healthy, sustainable well-being, Krebs told me. The company collaborates with fashion brands that are willing to learn and adjust their practices to include the green fibers, and even pay more for sustainable solutions.

Renana Krebs considers algae as one of the most influential resources for sustainable development, and notes that she gets requests from companies outside the fashion industry.

Over in San Diego, California, the startup Algenesis has been using algae oil as a replacement for petroleum. The two first products launched by the startup, whose founders are all surfers, are a surfboard and flip flops made from an algal biopolymer that is biodegradable.

In addition to fashion, algae can also be used to produce sustainable alternatives to everyday petrochemical products. For example, the startup Living Ink, in the US, aims to provide an eco-friendly alternative to printing ink using cyanobacteria.

After some initial hiccups, algae seem to be finding their way into the market. The new generation of startups in this field focus more on business-to-business relationships but build their branding around customers demand for environmentally friendly products.

It seems clear that cyanobacteria and algae will not replace bacteria and yeast as fermentation organisms in traditional applications. However, they have unique characteristics and a potential waiting to be unlocked by more research and daring business ideas. I cannot see limitations to what can be done with algae, but our own imagination, noted Crozet.

Cover illustration by Elena Resko, pictures courtesy of AlgaEnergy and AlgaLife

Read the original here:
After Years of Neglect, Algae Biotechnology Makes a... - Labiotech.eu

New technologies are emerging within the separation systems relating to chromatographic devices and consumables biotechnology. This is attracting many new players in the market. The emergence of technology is behind the growth of the separation systems for commercial biotechnology.

Read Report Overview - https://www.transparencymarketresearch.com/separation-systems-commercial-biotechnology-market.html

The key players within the market are: Merck KGaA, Thermo Fisher Scientific, Inc., Waters Corporation, Danaher Corporation, GE Healthcare, Dickinson and Company, and Becton. Of these, Danaher Corporation is dominating the market on account of its advanced technological innovations, states Transparency Market Research (TMR).

According to the report by TMR, the separation systems for commercial biotechnology market is expected to grow steadily on account of various companies being keen to explore this sector. As per the report, the market will be worth US$19,227.8 mn by the end of 2023. On the basis of application, the life sciences research and diagnostics segment is likely to continue to lead.

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2104

Europe is anticipated to lead in the market in terms of geography. The region is home to some of the biggest well-established firms which are involved in developing advanced chromatography technologies and solutions, which contributes to the growth of separation systems for commercial biotechnology market.

Increasing Investments in R&D Boosting Markets Growth

One of the key factors boosting the growth of the global separation systems for commercial biotechnology market is the growing investments in research and development. The participation by government agencies and the increasing number of biotech companies are other factors helping the market to grow. The advancements and the subsequent increase in the demand for microarray technology is also contributing to the growth of the separation systems for commercial biotechnology market.

Request for Analysis of COVID-19 Impact on Separation Systems for Commercial Biotechnology Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=2104

Lab Automation to Aid Markets Growth

The dropping costs of developing new technology and experimenting on account of lab automation will also go a long way towards the growth of the separation systems for commercial biotechnology. Thanks to lab automation, samples are processed at relatively low cost and is contributing extensively to the growth of the separation systems for commercial biotechnology market.

Across geographical regions, several conferences are held so as to spread the awareness level and educate organizations regarding the latest and emerging developments. The other reason for holding these conferences are for investments, proposing grants, mergers, and asking for funds for experimentation.

Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=2104

Increasing Interest by Pharmaceutical Companies to Push Markets Growth

Separation systems for biotechnology is implemented across biological products such as proteins, nucleic acid, and cell cultures and therefore holds an important status within the biotechnology and pharmaceutical Industries. The increasing interest by pharmaceutical products across the globe is behind the rising demand for separation systems for commercial biotechnology.

Buy Separation Systems for Commercial Biotechnology Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=2104&ltype=S

Extensive research is held in the field of Life Sciences such as bio separation procedures are expected to create a strong impact for the separation systems for commercial biotechnology market.

Browse More Trending Reports by Transparency Market Research:

Meniscus Repair Systems Market: https://www.transparencymarketresearch.com/meniscus-repair-systems-market.html

Hazmat Suits Market: https://www.transparencymarketresearch.com/hazmat-suits-market.html

Stroke Post Processing Software Market: https://www.transparencymarketresearch.com/stroke-post-processing-software-market.html

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

ContactMr. Rohit BhiseyTransparency Market ResearchState Tower,90 State Street,Suite 700,Albany NY - 12207United StatesUSA - Canada Toll Free: 866-552-3453Email: sales@transparencymarketresearch.comWebsite: https://www.transparencymarketresearch.com/

View post:
Separation Systems for Commercial Biotechnology Market: Rising Research and Development Activities to Encourage Market Growth - BioSpace

Unilever has announced to invest 1bn globally to eliminate fossil fuels as a source of carbon in its cleaning products by 2030.

The investment is part of Unilevers new Clean Future initiative aims at replacing 100% of the carbon derived from fossil fuels in the companys cleaning and laundry product formulations with renewable or recycled carbon. Clean Future embeds the circular (bio)economy principles into both packaging and product formulations at the scale of global brands to reduce their carbon footprint. This move is set to transform the sustainability of global cleaning and laundry brands including Sunlight, Cif, and Domestos.

Unilever said it is committed to turn away iis business from fossil-fuel sources of carbon to captured carbon dioxide, plants and biological sources, marine sources such as algae, and carbon recovered from waste materials.

Most cleaning and laundry products available today contain chemicals made from fossil fuel feedstocks, which maks up 46% of the carbon footprint in Unilevers current cleaning and laundry products across their life cycle. By transitioning away from fossil fuel-derived chemicals in product formulations, Unilever expects this initiative alone to reduce the carbon footprint of the product formulations by up to 20%. As part of Clean Futures impact in the UK, Unilever's Persil brand has just completely reformulated its liquid detergent using plant-based stain removers and will be launched this month.

Unilevers move to renewable or recycled sources of carbon for these chemicals is a deliberate shift away from the fossil fuel economy. The first initiative of its scale, Clean Future is a critical step towards Unilevers pledge of net zero emissions from its products by 2039.

Clean Future is our vision to radically overhaul our business," said Peter ter Kulve, Unilevers President of Home Care. "As an industry, we must break our dependence on fossil fuels, including as a raw material for our products. We must stop pumping carbon from under the ground when there is ample carbon on and above the ground if we can learn to utilise it at scale. We cannot let ourselves become distracted from the environmental crises that our world our home is facing. Pollution. Destruction of natural habitats. The climate emergency. This is the home we share, and we have a responsibility to protect it.

Unilever's 1bn investment for Clean Future will finance biotechnology research, CO2 utilisation, low carbon chemistry, biodegradable and water-efficient product formulations, and will halve the use of virgin plastic by 2025. This investment will also support the development of brand communications that make these technologies appealing to consumers.

Peter ter Kulve concludes: A new bioeconomy is rising from the ashes of fossil fuels."

Read this article:
Unilever to replace fossil carbon in cleaning products - European Biotechnology News

TEHRAN Iran is playing the leading role in the region in the fields of fintech, ICT, stem cell, aerospace, and is unrivaled in artificial intelligence, Sourena Sattari, the vice president for science and technology, told the Tehran Times in an exclusive interview on Saturday.

He went on to say that in terms of biotechnology Iran is at the forefront by producing 24 biomedicines.

U.S. sanctions caused exports of knowledge-based companies to decline three years ago, however, it has returned to growth and is projected to reach the pre-sanctions level of more than $1 billion by the end of the current [Iranian calendar] year (March 20, 2021), he emphasized.

Production of COVID-19 test kits

Referring to the domestic production of COVID-19 test kits, Sattari highlighted that some of the knowledge-based companies reached a production capacity of more than 200-300 thousand diagnostic kits per day.

Currently, 6 companies have been approved to produce these kits, and a newly-approved company recently was tasked with the production of 1.5 million kits, he added.

Pointing out that multiplying the production of COVID-19 equipment led to a significant foreign currency saving for the country, he said it also helped us cope with problems and not to run out of equipment because no matter how much money we gave, no country had the equipment to sell.

In such a condition, we were not only able to quickly adapt and produce all needed equipment, but to produce some manufacturing machines, and considerably reduce imports.

He went on to emphasize that the country not only can fully meet its need for diagnostic kits, but there is a great export potential.

Export-oriented firms supported

We have so far sent medical and self-protective equipment to many countries for fighting COVID-19, Sattari said, adding, there are 30 centers in other countries to follow up on export confirmation, as some knowledge-based products take up to 10 years to receive export approval.

So far, over six medicines have received export confirmation in Russia and are being exported, he noted, stating that, due to the complexities of exporting knowledge-based products, we have prepared plans to support export-oriented startups.

To support exporters, we pay up to 90 percent of the cost of obtaining standards and patent registration, the cost of registering products in foreign countries, as well as provision of significant financial assistance for participation in foreign exhibitions, in addition to granting them low-interest loans, and most importantly, we analyze export opportunities for the companies and help them find the proper export market. In other words, we provide them with comprehensive information, he explained.

Students abroad highly supported to return

Unfortunately, there is not a large number of Iranian students abroad, only a total of 50,000 students, which is over 1 percent of our total student population, and this number is not satisfactory, but the quality of students abroad is good and that is why we have been working hard on policies to bring them back since the past four years, he stated.

Sattari went on to note that so far, more than 1,800 students have returned from the top 100 universities in the world, nearly 400 of whom have been graduated from the worlds top 20 universities. Our supports are in the form of a different package of features, and we provide all the communications for them before they return.

The return trend has intensified after the pandemic, previously 1.5 people returned to the country per day, but now it has reached more than 2 people, he highlighted.

There is another issue, for example, some students decide to return for a short period and hold various workshops and courses in universities and research centers, for whom we also provide financial support, Sattari noted.

Record sale of $28.5 billion

"Knowledge-based companies promoted a new culture in the country that does not have physical assets but generates millions of dollars through producing knowledge.

Fortunately, last year, companies achieved a record sale of 1.2 quadrillion rials (nearly $28.5 billion at the official rate of 42,000 rials), which is expected to increase by 40 percent this year.

To date, 42 knowledge-based companies with a total value of 2.8 quadrillion rials (nearly $66.6 billion) have been listed on the stock exchange and they will soon turn into the biggest businesses in the county," Sattari said.

Potential to produce eco-friendly cars

Car manufacturing has been a monopolized system and breaking it was not that easy, since the beginning, the country's car manufacturing was more of a factory or assembly system so that it has not been moving toward an innovative approach.

But the most important thing in automobile production is a strong research and development department, and we are taking measures to help them produce some auto parts that have been previously imported, yet there would be no reform in the countrys car manufacturing industry.

We are working on smart and electric cars and two active sections are conducting research and development in this field, and we are seriously pursuing it.

Knowledge-based companies have the potential to produce eco-friendly cars, but it takes time to make changes in the industry.

Dealing with environmental issues

Pointing to the activities taken to counter environmental problems, Sattari stated that the firms have so far been developing advanced technologies to address different environmental issues, such as wastewater treatment, water purification, fighting sand and dust storms, alternative cultivation patterns, etc.

Hi-tech tackling environmental issues highly depend on environmental economics which is a sub-category of economics concerned with environmental issues. Particular issues include the costs and benefits of alternative environmental policies to deal with air pollution, water quality, toxic substances, solid waste, and global warming, he suggested.

Environmental economics emphasizes on strong sustainability and rejects the proposition that human-made (physical) capital can substitute for natural capital, he added.

We can never have an environment-based economy if we do not price environmental problems, and the government must enter to tackle any issues, but when there is an economic solution, people will engage and the issue is solved sustainably.

For example, to control a sand and dust storm hotspot, if the government enters, it can solve the problem by mulching for a while, but if businesses enter, an economic aspect will be formed and they can generate revenueandcounterthe environmental problems.

Knowledge-based economy is key to success

Referring to the vision for the next ten years, he said that we are changing the orientation and attitude of universities, and they have changed dramatically in the last five years. The orientation of universities must be solving people's daily problems while earning a significant portion of their revenue from selling technological advances to industries.

We win when the knowledge-based economy becomes the first economy of the country. If this happens, universities will also find their place in society. The difference between a creative and educated person and an ordinary one gets more clear. In a knowledge-based economy, the foundation of change is human, not underground resources, he highlighted.

Sattari went on to emphasize that we are vigorously developing technology centers and expanding all knowledge-based elements, concluding. We have made a serious change in science and technology, but in the next ten years, these changes must be evident in people's daily lives, more importantly, moving towards smart cities.

FB/MG

Read the original here:
Iran is pioneer in biotechnology, ICT, and artificial intelligence in region: VP - Tehran Times

A rating of 24 puts Amarin Corporation plc (AMRN) near the bottom of the Biotechnology industry according to InvestorsObserver. Amarin Corporation plc's score of 24 means it scores higher than 24% of stocks in the industry. Amarin Corporation plc also received an overall rating of 36, putting it above 36% of all stocks. Biotechnology is ranked 29 out of the 148 industries.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 36 would rank higher than 36 percent of all stocks.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Amarin Corporation plc (AMRN) stock is higher by 0.89% while the S&P 500 is down -0.59% as of 10:37 AM on Thursday, Sep 3. AMRN is up $0.05 from the previous closing price of $5.04 on volume of 21,043,437 shares. Over the past year the S&P 500 is up 21.17% while AMRN is down -68.46%. AMRN lost -$0.04 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Amarin Corporation plc (AMRN) Stock.

Go here to read the rest:
Is Amarin Corporation plc (AMRN) a Winner in the Biotechnology Industry? - InvestorsObserver

A rating of 95 puts Novavax, Inc. (NVAX) near the top of the Biotechnology industry according to InvestorsObserver. Novavax, Inc.'s score of 95 means it scores higher than 95% of stocks in the industry. Novavax, Inc. also received an overall rating of 80, putting it above 80% of all stocks. Biotechnology is ranked 29 out of the 148 industries.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Novavax, Inc. (NVAX) stock is up 7.19% while the S&P 500 is down -0.59% as of 10:42 AM on Thursday, Sep 3. NVAX is higher by $7.40 from the previous closing price of $102.90 on volume of 3,449,631 shares. Over the past year the S&P 500 has gained 21.17% while NVAX is higher by 1890.97%. NVAX lost -$2.75 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Novavax, Inc. (NVAX) Stock.

Originally posted here:
Is Novavax, Inc. (NVAX) a Winner in the Biotechnology Industry? - InvestorsObserver

Introduction: Global Agricultural Biotechnology Market

The global Agricultural Biotechnology market research report is a well synchronized synopsis highlighting some of the most significant, real time research analysis that enable quick and efficient business discretion. The report is a quick reference point to make comply with reader understanding of the volatile market situations that collectively steer enormous growth opportunities in the global Agricultural Biotechnology market.

The report offers a resourceful outline highlighting various facets that encourage remunerative business decisions in the Agricultural Biotechnology market.

The report draws references of growth-oriented business strategies, concomitant competition, business decisions as well as includes references of dynamic segmentation that collectively ensure steady growth in the global Agricultural Biotechnology market.

Top Leading Key Players are:

Syngenta AG, Monsanto, DuPont, Performance Plants Inc., Global Bio-Chem Technology Group, and ADAMA Agricultural Solutions are some of the key players in this industry

Get Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Agricultural Biotechnology Market @https://www.adroitmarketresearch.com/contacts/request-sample/113

The report categorically sheds ample light on multiply market components such as major trends, persistent challenges as well as barriers and threats that significantly restrict growth in the global Agricultural Biotechnology market.

Additionally, to meet with manufacturer needs of opportunity hunting, the report specifically outlines crucial references about major opportunities that steer steady growth and sustainable revenue streams in the global Agricultural Biotechnology market.

COVID-19 Specific Analysis

This up-to-date research report compilation also entices readers to get equipped with ongoing market developments inclusive of unprecedented developments such as COVID-19 outbreak that has crippled businesses and industrial developments in a myriad ways.

The report is structured to highlight effective cues for growth oriented business decisions, allowing manufacturers and stakeholders in the Agricultural Biotechnology market to come up with growth friendly strategies and tactics.

In Agricultural Biotechnology report, participants financial assessments are also included which consists of an evaluation of gross margin, sales volume, cash flow, revenue outcomes, capital investment, and growth rate. That will allow clients to gain intact comprehension of participants financial strengths and position in the worldwide Agricultural Biotechnology industry. Their production capacity, plant locations, Agricultural Biotechnology manufacturing processes, production volume, product specifications, raw material sourcing, distribution networks, and international presence are also analyzed in the report.

Browse the complete report Along with TOC @ https://www.adroitmarketresearch.com/industry-reports/agricultural-biotechnology-market

Evaluating Scope: Global Agricultural Biotechnology Market

Vigorous research suggests that the global Agricultural Biotechnology market shall maintain a lucrative growth trail in the coming years, clocking a robust CAGR of xx% through 2020-27.

According to meticulous primary and secondary research endeavors on the part of our in-house research experts, the global Agricultural Biotechnology market is poised to trigger remunerative growth, ticking a total growth of xx million USD in 2020 and is further likely to amplify growth through the forecast tenure, witnessing over xx million USD by 2027.

The report also categorically endeavors to offer requisite understanding about market developments across historic and current perspectives, to make accurate forecast predictions.

Understanding Regional Growth Prognosis: Global Agricultural Biotechnology Market

Following sections of the report on global Agricultural Biotechnology market includes vivid details about region specific developments, also including details about country-specific events that collectively influence optimistic growth.

Additionally, significant details on major market players have also been roped in the report to replicate growth-oriented business discretion.

For Any Query on the Agricultural Biotechnology Market @ https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/113

About Us :

Adroit Market Research is an India-based business analytics and consulting company incorporated in 2018. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a Markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable Market insights to help create opportunities that increase their revenues. We follow a code- Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

Contact Us :

Ryan JohnsonAccount Manager Global3131 McKinney Ave Ste 600, Dallas,TX75204, U.S.A.Phone No.: USA: +1 972-362 -8199/ +91 9665341414

Read the rest here:
Agricultural Biotechnology Market 2020 by Company, Regions, Type and Application, Forecast to 2025 - Owned

DGAP-News: B.R.A.I.N. Biotechnology Research And Information Network AG / Key word(s): Quarter Results/Quarterly / Interim Statement 31.08.2020 / 08:30 The issuer is solely responsible for the content of this announcement.

BRAIN is pleased with its results for the first nine months of the 2019/20 financial year

Zwingenberg, Germany31 August 2020

B.R.A.I.N. Biotechnology Research and Information Network AG (BRAIN AG, ISIN DE0005203947 / WKN 520394) today published its results for the first nine months of the 2019/20 financial year. Accordingly, the BRAIN Group reports revenues of 29.6 million compared to 27.9 million in the same period of the previous year. Taking into account the deconsolidation of Monteil Cosmetics GmbH, this corresponds to organic growth of 12.2%.

Third quarter revenues increased by 8.4% to 9.6 million from 8.9 million in the same period last year. This growth was purely organic, achieved in both the BioScience and BioIndustrial segments.

"Particularly considering the general economic situation, we have achieved very good growth," says Manfred Bender, CFO of BRAIN AG. "The fact that this growth is more pronounced in our research-driven segment is again due to the higher business volume with existing customers as well as new contracts for tailormade solutions projects."

Development by segments

The BioScience segment generated revenues of 10.5 million in the reporting period, up 37.5% from the prior-year period. Adjusted EBITDA improved from -4.4 million to -3.1 million.

Revenues of the BioIndustrial segment, which is related to product sales, decreased by 5.9% from 20.3 million to 19.1 million in the reporting period. Organically, revenues here increased by 0.4 million or 2.1% from 18.7 million to 19.1 million. The adjusted EBITDA of the segment developed positively and increased by 9.2% from 2.3 million to 2.6 million. This corresponds to an adjusted EBITDA margin of 13.3% compared to 11.5% in the previous year.

The reasons for the weaker revenue growth in the product business are, in addition to the start of new production facilities in Cardiff (UK) and Bttelborn, the globally reduced demand for bioethanol and alcoholic beverages due to the Corona pandemic. The BRAIN subsidiary WeissBioTech supplies, among others, powerful enzymes to bioethanol producers and the wine industry.

Despite the ongoing Corona virus pandemic and the associated economic uncertainty, BRAIN AG is still confident to make further progress in the projected direction, albeit possibly at a slightly slower pace.

Key financials (first nine months of fiscal year 2019/20)

More detailed information on the financial results are available at http://www.brain-biotech.com/investors/financial-publications as part of the quarterly statement for the period ended 30 June 2020.

Financial Calendar:

http://www.brain-biotech.com/investors/financial-calendar

About BRAIN

B.R.A.I.N. Biotechnology Research and Information Network AG (BRAIN AG; ISIN DE0005203947 / WKN 520394) is one of Europe's leading technology companies in the field of industrial biotechnology, the core discipline of the bioeconomy. As such, BRAIN identifies previously untapped efficient enzymes, microbial producer organisms or natural substances from complex biological systems that can be put to industrial use. The innovative solutions and products developed by means of "Nature's Toolbox" are successfully applied in the chemicals, cosmetics and food industries.

BRAIN's business model is based on two pillars. The BioScience segment mainly comprises research and development business with industrial partners ("Tailor-Made Solutions" cooperation business), and the company's own research and development. The BioIndustrial segment consists mainly of business with industrially scalable products.

B.R.A.I.N.Biotechnology ResearchAnd Information Network AGDarmstdter Str. 34-3664673 ZwingenbergGermanywww.brain-biotech.com

Contact Investor RelationsMichael SchneidersPhone: +49-6251-9331-86Email: mis@brain-biotech.com

Contact MediaDr. Stephanie KonlePhone: +49-(0)-6251-9331-70Email: stk@brain-biotech.com

Disclaimer

This press release contains forward-looking statements. These statements reflect the current views, expectations, and assumptions of the management of BRAIN AG and are based on information currently available to the management. Forward-looking statements are no guarantees of future performance and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. There are numerous factors which could influence the future performance by and future developments at BRAIN AG and the BRAIN group of companies. Such factors include, but are not limited to, changes in the general economic and competitive environment, risks associated with capital markets, currency exchange rate fluctuations, changes in international and national laws and regulations, in particular with respect to tax laws and regulations, and other factors. BRAIN AG does not undertake any obligation to update or revise any forward-looking statements.

Follow BRAIN AG on Twitter (Twitter@BRAINbiotech) and LinkedIn (@BRAIN AG)

31.08.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at http://www.dgap.de

See the original post:
B.R.A.I.N. Biotechnology Research And Information Network AG: BRAIN is pleased with its results for the first nine months of the 2019/20 financial...

Cabaletta Bio Inc (CABA) is near the top in its industry group according to InvestorsObserver. CABA gets an overall rating of 63. That means it scores higher than 63 percent of stocks. Cabaletta Bio Inc gets a 77 rank in the Biotechnology industry. Biotechnology is number 28 out of 148 industries.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 63 would rank higher than 63 percent of all stocks.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

Cabaletta Bio Inc (CABA) stock is trading at $10.33 as of 2:22 PM on Wednesday, Sep 2, an increase of $0.53, or 5.41% from the previous closing price of $9.80. The stock has traded between $9.70 and $10.73 so far today. Volume today is less active than usual. So far 34,817 shares have traded compared to average volume of 87,035 shares.

Click Here to get the full Stock Score Report on Cabaletta Bio Inc (CABA) Stock.

Continue reading here:
Is Cabaletta Bio Inc (CABA) a Winner in the Biotechnology Industry? - InvestorsObserver

A rating of 85 puts Evogene Ltd (EVGN) near the top of the Biotechnology industry according to InvestorsObserver. Evogene Ltd's score of 85 means it scores higher than 85% of stocks in the industry. Evogene Ltd also received an overall rating of 66, putting it above 66% of all stocks. Biotechnology is ranked 28 out of the 148 industries.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 66 means the stock is more attractive than 66 percent of stocks.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

Evogene Ltd (EVGN) stock is trading at $2.82 as of 11:50 AM on Wednesday, Sep 2, an increase of $0.08, or 2.92% from the previous closing price of $2.74. Volume today is elevated. So far 1,124,639 shares have traded compared to average volume of 361,387 shares. The stock has traded between $2.47 and $2.95 so far today.

Click Here to get the full Stock Score Report on Evogene Ltd (EVGN) Stock.

Read more here:
Is Evogene Ltd (EVGN) The Right Choice in Biotechnology? - InvestorsObserver

The Field of Expertise Human & Biotechnology one of the five research focus areas of Graz University of Technology comprises research activities in the areas of Biomedical Engineer-ing and Biotechnology and includes researchers from the Faculty of Computer Science and Biomedical Engineering and the Faculty of Technical Chemistry, Chemical and Process Engi-neering, Biotechnology. Research results contribute to medicine, environmental technology, industry and agriculture, benefitting society in many aspects.

Graz University of Technology invites applications for an open-topic

Of particular interest is research in Biomedical Engineering (e.g. biomechanics, medical imaging, (clinical) bioinformatics, neural engineering, neuroprosthetics, brain-computer interfaces, computational and experimental electrophysiology, biomedical modelling, biomedical sensor technology, biomaterials) or Molecular Biomedicine (e.g. functional genomics, chemical biology, metabolism research) but also in Industrial Biotechnology (e.g. cell engineering, protein and enzyme engineering, bioprocess engineering, biocatalysis green chemistry, glycoengineering, synthetic biology, computational biotechnology, sensors for process technology) or Environmental Biotechnology (e.g. microbiome research and biotechnology, microbe-plant interactions, food chemistry and human sensors, enzymatic decomposition and modification of (bio-)polymers, use of renewable materials through biotechnological processes).

The professorship will be part of the Field of Human and Biotechnology described athttps://www.tugraz.at/en/research/forschungsschwerpunkte-5-fields-of-expertise/human-biotechnology/overview-human-biotechnology/

Based on the research and teaching focus, the candidate will be assigned to a matching institute and faculty that participate in this Field of Expertise.

Requirements:

Expected Qualifications:

To ensure effective international representation of the research group and its work, excellent spoken and written competence in English is required. Specifically, willingness to teach courses in English is expected. Fluency in German or the willingness to acquire it is also required. The successful candidate is also expected to transfer her/his residence to the area of Graz.

Graz University of Technology aims to increase the proportion of women, in particular in man-agement and academic staff, and therefore qualified female applicants are explicitly encour-aged to apply. Until a balanced ratio of men and women has been achieved at the university, preference will be given to women if applicants are equally qualified.

Graz University of Technology actively promotes diversity and equal opportunities. Applicants are not to be discriminated against in personnel selection procedures on the grounds of gen-der, ethnicity, religion or ideology, age, sexual orientation (Anti-discrimination). People with disabilities who have the relevant qualifications are expressly invited to apply.

Our Offer:

The advertised position is a tenure-track career position for an initial period of 6 years. (pursuant to 99 para. 5 of the Universities Act). After the conclusion of a qualification agreement, the job holder is appointed as an Assistant Professor. After a positive evaluation of the qualification agreement, the position will be turned into a permanent position as Associate Professor. Graz University of Technology provides excellent working conditions in a lively scientific community combined with the outstanding living quality of the Graz area.

The position will be paid according to category B1 of the collective agreement for employees of Austrian universities, stipulating an initial gross salary of EUR 4,309.30 (14 x per year).

Your Application:

Interested applicants are requested to send a detailed application in electronic form, and should quote the position identification number:

at the latest by September 30th, 2020 (date of email) to the Vice Rector of Research via the Research & Technology House of the Graz University of Technology, Horst Bischof, E-Mail: applications.foe@tugraz.at

The interviews for the position are expected to take place in the week from November 16th, 2020. Candidates are asked to be available in this period. For further questions, please contact the head of the Field of Expertise, Gernot Mller-Putz, E-Mail: gernot.mueller@tugraz.at

Vice Rector of Research: Horst BischofPosition identification number: 29/R/PA/93070/20

Go here to see the original:
Tenure-Track Assistant Professorship in the area of Human & - Nature.com

The global market for media, sera and reagents in biotechnology should reach $5.5 billion by 2023 from $4.1 billion in 2018 at a compound annual growth rate (CAGR) of 6.0% for the period 2018-2023.

Update Scope:

This late 2017 update leverages the structure of the early 2017 report, presenting all the same chapters and major headings, and repeating chapter introductions and other essential content to establish context for the updates. Within this structure, updates are designated with an asterisk (*).

All company profiles from May 2017 are included in the Appendix, along with new companies identified as part of this update.

Request For Report sample @ https://www.trendsmarketresearch.com/report/sample/11818

The scope of the report encompasses the major types of 3D cell culture that have been used, as well as the major applications being developed by industry, academic researchers and their commercialization offices, and government agencies. It analyzes current market status, examines future market drivers and presents forecasts of growth over the next five years. Technology developments, including the latest trends, are discussed. Other influential factors such as screening strategies for pharmaceuticals have also been included.

Update Includes:

An overview of the global markets and technologies for 3D cell cultures. Analyses of global market trends, with data from 2016, estimates for 2017, and projections of compound annual growth rates (CAGRs) through 2022. Information on 3D technologies, with a focus on representative platforms, including cube, spherical droplet, stacked plate, magnetic bead, and other platforms. Value-chain analysis at the following levels: key innovation or founding intellectual property, prototyping, beta testing, and research collaborations or relationship building. Analysis of the markets dynamics, specifically growth drivers, restraints, and opportunities. Relevant patent analysis, including recent activity and a list of key patents. Profiles of major players in the industry.

Report Summary

This report on 3D cell culture global markets and technology is a comprehensive review of the history of cell culture, current offerings and their adoption dynamics and progress, along with an informed projection of future growth. It contains a sufficient overview of tissue engineering to convey the important touch points, but it focuses on applications of cell and tissue culture as tools for drug discovery and safety testing. This update also reviews applications for development of regenerative medicine.

As background, the report begins in Chapter Three with an overview of tissues and cells, a summary of tissue and cell culture requirements and a brief recap of the history of cell culture, including early learnings from vaccine development.

As additional background and to set the context, Chapter Four provides an overview of the tissue and cell culture systems that have been developed over the past decades across many applications in research and industry. For example, over the past 30 years, 3D cell culture technology and early testing applications have been developed in concert with artificial skin substitutes (therapeutics), as illustrated via representative examples. A number of 3D technologies utilize tissue and cell culture systems calledbioreactors, and many other 3D technologies are often influenced by bioreactor and related developments. A revenue estimate for bioreactors and microcarriers used in 3D solutions is provided.

Key history and technology descriptions are provided in Chapter Five to set the context on the research landscape as additional background for the focus on drug discovery and drug safety testing. In this setting, researchers typically use labware such as T-flasks and Petri dishes with basic microscopes before graduating to microarray technology (e.g., microtiter plates, plate readers) with some going on to use high-content screening (HCS) technology. These tools rely heavily on fluorescence and other detection technologies that can be grouped under the science of cellomics. After an overview of cellomics and microarray technology, subsequent sections detail the ways these technologies are applied to the workings of assays, including cell-based assays, and describe the reagents, cells and other consumablesused in both traditional two-dimensional (2D) and increasingly in 3D cell culture to create new and improved assays. The chapter further describes the key types of assays commonly used in research, details the all-important category of cytotoxicity assays, and positions relevant examples of value-added 3D assay kits and services such as higher throughput (384 and 1536 well) format, kinetic metabolism applications and a case study on a new open innovation platform for 3D. Subsequent chapters detail key3D applications in cancer, toxicology/safety and stem cells.

Chapter Six details 3D cell culture technology types, including gels, scaffolds, bioreactors, hanging droplet platforms for spheroid growth and microchips. These are either sold as raw materials and products bundled onto microplates used by researchers in conjunction with reagents and other consumables to fabricate homebrew assays or as assay kits. This chapter describes the origin and current status on all 3D technologies, including substantial updates on 3D bioprinting and biochips A revenue estimate for 3D technologies and products is provided.

More Info of Impact Covid19 @ https://www.trendsmarketresearch.com/report/covid-19-analysis/11818

Here is the original post:
Global Markets For Media, Sera And Reagents In Biotechnology Market Future Forecast Assessed On The Basis Of How The Market Is Predicted To Grow -...

Technavio has been monitoring the marine biotechnology market and it is poised to grow by $ 2.5 bn during 2020-2024, progressing at a CAGR of over 8% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200901005119/en/

Technavio has announced its latest market research report titled Global Marine Biotechnology Market 2020-2024 (Graphic: Business Wire)

Although the COVID-19 pandemic continues to transform the growth of various industries, the immediate impact of the outbreak is varied. While a few industries will register a drop in demand, numerous others will continue to remain unscathed and show promising growth opportunities. Technavios in-depth research has all your needs covered as our research reports include all foreseeable market scenarios, including pre- & post-COVID-19 analysis. We offer $1000 worth of FREE customization

The market is fragmented, and the degree of fragmentation will accelerate during the forecast period. Aker BioMarine AS, BASF SE, CP Kelco, Cyanotech Corp., KD Pharma Group, L'Air Liquide SA, Lonza Group Ltd., Marinomed Biotech AG, PharmaMar SA, and Sea Run Holdings Inc. are some of the major market participants. To make the most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

View market snapshot before purchasing

The increase in demand for biofuel has been instrumental in driving the growth of the market.

Technavio's custom research reports offer detailed insights on the impact of COVID-19 at an industry level, a regional level, and subsequent supply chain operations. This customized report will also help clients keep up with new product launches in direct & indirect COVID-19 related markets, upcoming vaccines and pipeline analysis, and significant developments in vendor operations and government regulations. Download a Free Sample Report on COVID-19 Impacts

Marine Biotechnology Market 2020-2024: Segmentation

Marine Biotechnology Market is segmented as below:

Marine Biotechnology Market 2020-2024: Scope

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources. The marine biotechnology market report covers the following areas:

This study identifies the increasing application of seaweeds as one of the prime reasons driving the marine biotechnology market growth during the next few years.

Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Technavios in-depth research has direct and indirect COVID-19 impacted market research reports.

Register for a free trial today and gain instant access to 17,000+ market research reports.

Technavio's SUBSCRIPTION platform

Marine Biotechnology Market 2020-2024: Key Highlights

Table of Contents:

Executive Summary

Market Landscape

Market Sizing

Five Forces Analysis

Story continues

Market Segmentation by Application

Customer landscape

Geographic Landscape

Drivers, Challenges, and Trends

Vendor Landscape

Vendor Analysis

Appendix

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200901005119/en/

Contacts

Technavio ResearchJesse MaidaMedia & Marketing ExecutiveUS: +1 844 364 1100UK: +44 203 893 3200Email: media@technavio.com Website: http://www.technavio.com/

Read the original here:
COVID-19: Marine Biotechnology Market 2020-2024 | The Increase In Demand For Biofuel to boost the Market Growth | Technavio - Yahoo Finance

The 63 rating InvestorsObserver gives to Heat Biologics Inc (HTBX) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 77 percent of stocks in the Biotechnology industry, HTBXs 63 overall rating means the stock scores better than 63 percent of all stocks.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Heat Biologics Inc (HTBX) stock is trading at $1.26 as of 9:52 AM on Monday, Aug 31, a decline of -$0.08, or -5.97% from the previous closing price of $1.34. The stock has traded between $1.25 and $1.36 so far today. Volume today is below average. So far 1,467,087 shares have traded compared to average volume of 35,406,604 shares.

To see InvestorsObserver's Sentiment Score for Heat Biologics Inc click here.

Original post:
Is Heat Biologics Inc (HTBX) Stock Near the Top of the Biotechnology Industry? - InvestorsObserver